Drug
Volociximab clinical trials
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How studies write it
Studies that test it under each name
Development codes
- M200
- 1
Studies by the year they started
10 studies that test it; most in 2005 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Abbott (3) · AbbVie (prior sponsor, Abbott) (2) · Ophthotech Corporation (1) · AbbVie (1) · PDL BioPharma, Inc. (1) · Facet Biotech (1) · Jonsson Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses volociximab is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular DegenerationCompletedPhase 1Ophthotech CorporationNCT00782093Written as volociximab
- A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1AbbVieNCT00654758Written as M200 (Volociximab), Carboplatin, Paclitaxel
- Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerStatus unknownPhase 2Jonsson Comprehensive Cancer CenterNCT00278187Written as volociximab
- A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic CancerCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00401570Written as Volociximab
- Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)CompletedPhase 1/2AbbVie (prior sponsor, Abbott)NCT00635193Written as M200 (Volociximab)
- A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal CancerTerminatedPhase 2Facet BiotechNCT00516841Written as Volociximab
- A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1AbbottNCT00666692Written as M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
- A Study of Volociximab in Metastatic MelanomaTerminatedPhase 2AbbottNCT00369395Written as volociximab
- Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)TerminatedPhase 2AbbottNCT00100685Written as Volociximab (anti-α5β1 integrin monoclonal antibody)
- Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With ChemotherapyCompletedPhase 2PDL BioPharma, Inc.NCT00099970Written as M200 (volociximab) in Combination with Dacarbazine (DTIC)
Codes
What other systems call volociximab · ClinicalTrials.gg INT005029
- MeSH (NLM) C516631volociximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 496K5Z02NWVOLOCIXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q7940537VolociximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48426VolociximabOne source FDA
- DrugBank DB06647One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C516631 | volociximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 496K5Z02NW | VOLOCIXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q7940537 | Volociximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48426 | Volociximab | One source FDA |
| DrugBank | DB06647 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.